Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLET: Aflibercept Dosing Regimens in DME
NCT02818998Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started Nov 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02818998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818998.